Compare Novartis AG (NVS) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Wendys Co — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Wendys Co trades at $6.22 (market cap $1.19B). The key difference: Novartis AG is far larger — about 225.7× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Wendys Co for 77 Days on average.
| NVS | WEN | |
|---|---|---|
Market Cap | $268.57B | $1.19B |
Volume | 1,532,573 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $9.33 |
52-Week Low | $121.80 | $6.10 |
Typical Hold Time | 82 Days | 77 Days |
Enterprise Value | $309.89B | $4.92B |
Dividend Yield | 3.31% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Wendy's stock (WEN) trades at $6.11, down 0.81% recently, with a bearish technical signal and oversold RSI indicators. The company shows mixed fundamentals: it has beaten earnings estimates for three consecutive quarters but faces declining net income margins and high debt levels. Recent news highlights challenges, including a major franchisee bankruptcy and same-store sales declines, contributing to negative sentiment.
The outlook for WEN is cautious. While its low P/E ratio of 9.25 and consistent earnings beats offer value, risks from franchisee instability, competitive pressures, and declining profitability weigh on growth. Analyst consensus is a 'Hold' with a $7.58 price target, suggesting limited upside amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
